Camber launches generic Vimpat Injection
PISCATAWAY, N.J. – Camber Pharmaceuticals announces the addition of Lacosamide Injection, USP to its current portfolio. Lacosamide Injection is indicated for treatment of partial-onset seizures in patients 17 years of age and older. Camber’s 200 mg/20 mL (10 mg/mL) strength of Lacosamide Injections is available in a 10 pack of single-dose vials. To find out
